CC
MRTX

Clearline Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Clearline Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,275
Closed -$3.01M – 141
2023
Q4 		$3.01M Hold
51,275
– – 0.18% 63
2023
Q3 		$2.23M Sell
51,275
-5,066
-9% -$181K 0.19% 83
2023
Q2 		$2.04M Buy
+56,341
New +$2.32M 0.12% 73

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Clearline Capital's MRTX Position: Q1 2024 in Review

Clearline Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 51,275 shares — an estimated $3.01M sold.

Clearline Capital first reported a position in MRTX in Q2 2023 and held it in 3 quarters. The position peaked at $3.01M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Clearline Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Clearline Capital sold 51,275 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.01M.
  • Clearline Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Clearline Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $3.01M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Clearline Capital's 13F filing for Q1 2024, filed 15 May 2024.